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Abstract
Background: Bladder cancer is a major worldwide health problem. Diagnosis of acute and chronic bladder carcinoma is based on
the detection of a number of tumor markers such as nmp22 (nuclear matrix protein 22). Nmp22 is one of the tumor markers used
for detecting the recurrence of bladder cancer.
Objectives: The aim of this study was to develop hybrid cell producing monoclonal antibodies (MAbs), specifically for nmp22 using
hybridoma technology.
Materials and Methods: Complete and incomplete adjuvant with recombinant truncated nmp22 antigens were emulsified and
injected to BALB/c mice. The spleen was removed and the splenocytes were fused with sp2/0 myeloma cells. Characterization of the
produced mAb was carried out.
Results: As a result of the fusion, hybridoma cells were produced and exhibited high- titer antibodies. By testing of colons based on
the Enzyme Linked Immunosorbent Assay (ELISA), 135 hybridoma colons were selected, out of which eight high titer clones including
54D-6F-2E-36-7H-2A-8E-1D-6D were detected and one of the clones named FPR92 was selected, and the produced mAb was further
characterized. The produced antibody belongs to the IgG class and its light chain was kappa. With respect to affinity, the mAb was
included as high affinity 3× 10-7 reacting with NMP22 recombinant protein .The western blot of cancerous bladder tissue showed
the presence of 40 and 55 kD proteins as major bands that reacted with this mAb.
Conclusions: Based on a double limiting dilution protocol, a type of monoclonal antibody, named FPR92 was produced and char-
acterized.
Keywords: Nmp22, Hybridoma, mAb, FPR92, Characterization
1. Background
In Iran, bladder cancer has been found as the most
common urological cancer among the general population
(48.3%) (1, 2). It is the 4th most common cancer in males and
it is amongst the top five newly diagnosed cancers in males
(3, 4). Bladder cancer has been ranked second in the clas-
sification of genitourinary malignancies. Most compara-
tive studies have shown that molecular biomarkers have
high sensitivity for prediction of outcomes of bladder can-
cer that could help clinicians provide individualized prog-
nostic actions (5). Noninvasive urine-based biomarkers,
including nuclear matrix protein 22 (NMP22) (6, 7), with
methods such as fluorescence in situ hybridization (FISH)
(8), bladder tumor antigen (BTA) and immunocyt detec-
tion of bladder cancer, have generated better-quality and
diagnostic accuracy (9). The NMPs are an essential part
of a three-dimensional network of the nucleus that local-
izes to the spindle poles during mitosis (9, 10). The NMP22
regulates the distribution of chromatids to daughter cells
(9, 11). By serving as an attaching point for enzymatic ma-
chines, it plays significant roles in DNA replication, tran-
scription, RNA processing and gene expression. This anti-
gen is released from dying urothelial cells and can be mea-
sured in the urine. There are some variations in NMP com-
position in human tumors such as breast, prostate, colon,
cervical, renal, and head and neck cancer (12). Because tu-
mor markers can be measured by immunologic assay tests,
these have potential applications to present objective mea-
surable results (13). Currently, beneficial monoclonal anti-
bodies comprise over 30% of biopharmaceuticals in clin-
ical trials (14). Also, monoclonal antibodies are applied
for research components and preparing diagnostic kits
such as enzyme-linked immunosorbent assay (ELISA) and
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immunofluorescence of numerous diseases (15). Mono-
clonal antibody based tests have been considered to mea-
sure levels of fragmented NMP22 from bladder tissues with
great specificity and can be created in large quantities
(16). They allow measureable assessment of the forms of
the mitotic apparatus in voided urine for recurrence of
NMP-22 as a marker of tumor relapse. Thus, these biologi-
cal reagents (monoclonal antibody) have been used exten-
sively as probes for studying tumor markers and character-
ization of a wide range of tumors (17).
2. Objectives
The aim of this study was to generate a series of mon-
oclonal antibodies with basic protocols for mouse immu-
nization, cell fusion and selection using a truncated re-
combinant antigen (nmp 22).
3. Materials and Methods
3.1. Source of Immunogen
Recombinant truncated nmp22 was provided by the
Tarbiat Modares university, school of medical sciences, and
department of medical biotechnology. In this antigen, the
300 amino acids of N terminal was cloned and expressed
in E. coli BL21.
3.2. Immunization
Eight-week-old female BALB/c mice were immunized
with recombinant nmp22. A solution containing 15 µg of
recombinant nmp22 antigen was prepared in phosphate-
buffered saline (PBS: 10 mM K2HPO4, 10 mM KH2PO4, 0.15
mM NaCl, pH 7.2) and mixed with equal volumes of Fre-
und’s complete adjuvant (Sigma). The stability and qual-
ity of the emulsion was carefully checked. This solution
(0.5 mL) was given by intra peritoneal injections. Second
and third injections were carried out using Freund’s in-
complete adjuvant (Sigma) at three weekly intervals. A
booster comprised of 30 µg of nmp22 antigen in 100 µL
PBS without adjuvant was injected four days before fusion
(18). Blood samples were collected for estimating the im-
mune response by ELISA. Furthermore, 100 µL of recombi-
nant antigen NMP22 (1 µg/mL in BPS) was coated in ELISA
wells. The wells were washed with PBS buffer and blocking
was carried out by 0.1% skim milk solution for one hour at
37°C. The content of the wells were removed and the plate
was washed three times with phosphate buffered saline
and 0.05% Tween-20 (PBST) buffer. In the following 100-µL
mouse serum was added to the wells at 1/500, 1/1,000 and
1/2,000 dilutions. Also the normal mouse serum was added
at a concentration of 1/500 to the wells as negative control.
After a one-hour incubation, the plate was washed three
times with PBST buffer. One hundred microliters of 1: 2000
dilution of horseradish peroxidase (HRP)-conjugated anti-
mouse IgG antibody was added to the wells and was incu-
bated for one hour at 37°C. The 100-µL substrate was then
added and after 10 minutes the reaction was stopped with
100 µL of 2 M HCl and the absorbance was read on a micro
plate reader at 450 nm.
3.3. Cell Fusion and Antibody Production
Lymphocytes of spleen cells were used for antibody
source. Spleen cells were suspended in 10 mL of the serum-
free RPMI and washed five times in the same buffer. SP2/0-
Ag14 myeloma and spleen cells were mixed in a 50-mL
conical centrifuge tube at 1: 2 ratio. Lymphocytes from
the spleen cells were fused with SP2/0-Ag14 myeloma cell
in the presence of 50% polyethylene glycol (PEG) (Merck).
Polyethylene Glycol was added slowly over a one-minute
period while gently stirred and kept without any stir-
ring for another one minute. After centrifugation (8000
g, five minutes, 4°C), the fusion suspension was diluted
by adding 4 mL of RPMI medium (Gibco) containing 15%
Fetal Calf Serum (FCS), 20% Hypoxanthine-Aminopterin-
Thymidine medium (HAT) and antibiotics (plasmocin,
penicillin and streptomycin) drop by drop over a period of
two minutes. The fusion suspension was then diluted with
40 mL of the same media at a rate of 10 mL per minute. The
suspension was plated on 96-well plates that were covered
with feeder cells (120µL per well) and incubated overnight
at 37°C, 5% CO2 and 95% humidity. After eight to nine days,
50 µL of RPMI medium containing 15% FCS, 5% HAT and
antibiotic (plasmocin, penicillin and streptomycin) was
added to each well. After six to seven days, the wells were
screened for presence of efficient antibody by using indi-
rect ELISA (18).
3.4. Calculation of the Affinity of FPR92 Monoclonal Antibody
The supernatant of colons was prepared by culturing
in RPMI medium with minimum concentration of FCS, fol-
lowed by antibody purification from FPR92 clone super-
natant. Protein concentration was assayed using the Brad-
ford method. Different concentrations of recombinant
antigen NMP22 (1, 0.5, 0.25 and 0.125 µg/mL in BPS) were
coated in ELISA wells separately, followed by 45 minutes
of blocking with 5% skimmed milk-PBS at 37°C. Further-
more, 1: 4000, 1: 2000, 1: 1000 and 1: 500 dilutions of pu-
rified antibodies of FPR92 clone were prepared in PBS and
added to ELISA wells. Next, the plate was washed three
times with PBST buffer and incubated with 100 µL of 1:
2000 dilution of horseradish peroxidase (HRP)-conjugated
antimouse IgG antibody, and gentle shaking carried out
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for one hour at 37°C. After five times of washing, 100 µL of
substrate was added to the wells and after 10 minutes the
reaction was stopped with 100 µL of 2 M HCl and the ab-
sorbance was read on a micro plate reader at 450 nm.
3.5. Screening of Hybridoma
The screening of hybridoma supernatant was per-
formed by indirect ELISA. Wells of ELISA plates were coated
with 100 µL of nmp22 antigen at a concentration of 1
µg/mlL in PBS buffer and incubated at 37°C overnight. The
wells were washed with PBS buffer and blocking was car-
ried out by 0.1% skim milk solution for one hour at 37°C.
The contents of the wells were removed and the plate was
washed three times with PBST buffer (18).
Supernatants of the hybridoma from each culture was
added to the wells (100 µL per well) and incubation was
done at 37°C for one hour. Washing with PBST was per-
formed for five times, then 100 µL of proper dilution of
anti-mouse antibody labeled with HRP was added to each
well and incubated for one hour at 37°C. The supernatant
of SP2/0 was used as a negative control. At the end of the
incubation time, the wells were washed three times with
PBST and 50 µL of Tetramethylbenzidine (TMB) solution
was added to each well as substrate. Stopping of the re-
action was performed by adding 50 µL of 1N HCl and ab-
sorbance was detected at 450 nm (19).
3.6. Cloning by Limiting Dilution
Sub cloning by limiting dilution that resulted in sin-
gle cell secreting monoclonal antibodies was performed.
The number of hybridoma cells was calculated until it
reached four, two and one cell per well in 10% FCS-RPMI. The
sizes of the produced hybridoma clones were checked and
the numbers of wells including single hybridoma clone
were determined 4, 6, 10 and 14 days after cultivation.
The plate was incubated at 37°C in a 5% CO2 incubator.
Single hybridoma clone-producing antibody was assessed
by indirect ELISA, as described in previously. Finally, hy-
bridoma clone-producing antibodies were selected with
desired affinity (18, 19).
Each result was confirmed by triplicate repeats.
3.7. Purification
Purification of MAbs was performed using protein
G-Sepharose column affinity chromatography. The hy-
bridoma supernatant was precipitated at 40% to 50%
(NH4)2SO4 saturation, whereas other proteins persisted
in the solution. After centrifugation, the supernatant was
removed and the precipitate was dissolved in phosphate
buffer (PB) and the solution was dialyzed against PB buffer
overnight, with three changes. Purification was performed
by protein G-based immunoaffinity chromatography in
which the acidic elution buffer (0.1 M glycine-HCl pH 2.8)
was added and fractions were collected from the column.
The acidic condition separated the antibody from the im-
mobilized protein G and the IgG was improved in its puri-
fied state (18).
3.8. Immunoprecipitation of the Antigen and Blotting
Native Numa (nuclear mitotic apparatus protein) was
extracted by immunopercipitation of Numa from a blad-
der cancer cell line (HN-5 gifted by department of genetic,
Tarbiat Modares university). Bladder cancerous cells were
lysed with lysis buffer (containing 20 mM tris, 100 mM
EDTA, 100 mM EDTA in 150 mL NaCl, triton X 100, 2.5 mM
phosphate, 1 mM β glycerol, 1 mM Na3PO4, 1 µg/mL Leu-
peptin, Tris 187.5 mM. pH = 6.8) (20). Cell lysates were cen-
trifuged (12000 g for 10 minutes at 4°C) to remove cell de-
bris, and protein concentration was assessed by the Brad-
ford method. Furthermore, 300µL of lysate was incubated
with 12µg of G100 (Sigma) treated by anti Numa polyclonal
antibody (produced against truncated antigen of Numa,
gifted by TMU) for one hour at 4°C. Immunoprecipitates
were washed three times with the same lysis buffer and re-
suspended in the sample buffer containing glycine buffer
pH 2. The resulting solution was centrifuged and the super-
natant was removed; the pellet was run on 15% tris-glycine
sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) under reducing conditions and transferred
to nitrocellulose membranes for immunoblotting analy-
sis, using the produced monoclonal antibody (21). A sim-
ilar procedure was applied for cancerous tissues obtained
from a bladder cancer patient. Briefly, the tissue was col-
lected and 1 mg was weight out, treated with the mikro-
dismembrator apparatuses (5 minutes at 20 rpm), added
to PBS (10 mM pH 7), centrifuged and measured for protein
content. Finally 10 µg was used for electrophoresis.
3.9. Western Blotting
Western blot analysis was performed with a Bio-Rad ap-
paratus (running buffer: 0.1% (w/v) sodium dodecyl sul-
fate (Merck, Darmstadt, Germany), 191.8 mM glycine (pH
8.2) and 5% (v/v) 2-mercaptoethanol (Merck)). For Western
blotting the gel was run at room temperature at constant
voltages (100 V (for 50 minutes. The protein was trans-
ferred to the nitrocellulose membrane with 0.2 pm pore
size. The nitrocellulose membrane was washed with TBST
(tris-buffered saline with Tween 20: 50 mM Tris, 150 mM
NaCl and 0.05% Tween 20, pH 7.4) and was blocked with 5%
skim milk in TBST for one hour. The membrane was washed
and incubation was done overnight with 5 mL (3 ug /mL) of
produced monoclonal antibody. After washing with TBST
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(three times for 10 minutes), a second antibody-HRP label
was added to nitrocellulose and incubated at 37°C for 45
minutes. Finally, DAB /H2O2 was added as the substrate (18,
22).
3.10. Determination of Antibody Class and Subclass
Antibody class determination kit (Roche) was used for
isotype and light chain determination. For this purpose
based on company instruction, the dilution of 1: 20 of sin-
gle clone supernatant was prepared. One hundred micro-
liters of supernatant was added to the indicator solution.
After 10 minutes the results were read on the isostrip.
3.11. Statistical Methods
The data were statistically analyzed using SPSS version
16 software. Statistical significance was set at P < 0.05.
4. Results
4.1. Mouse Polyclonal Antibody Titer
Table 1 shows the results of the titration of polyclonal
antibody against recombinant protein NMP22. As it is clear
from the results, a high difference exists between the re-
action for normal mouse serum and the serum of immu-
nized mice.
4.2. The Results of Hybridoma Formation
Initially, 135 clones were obtained from the first fusion
step. The optical density of antibody production was be-
tween 2.5 and 3, and some times over 3. They were selected
and monitored continually for antibody production. Table
2 shows the results of the first screening.
4.3. Screening the Best Clones for Further Investigation
After a few days, clones were screened with indirect
ELISA using NMP 22 as the antigen. The optical densities of
15 clones was found to be appropriate for limiting dilution
and their OD at 450 nm was found to be stable and their
macroscopic investigation showed proper viable cells (Ta-
ble 3).
4.4. Determination of the Class and Subclass and Light Chain
Type of Monoclonal Antibody
Figure 1 shows the immunochromatography of the
strip test for class and subclass determination of the anti-
body (clone FRP92). As indicated, the antibody is of type
IgG2 containing kappa light chain.
Figure 1. Detection of the Class and Subclass of MAbs (FPR92) Produced in This Study
A band shows the class antibody (IgG), C band shows type of light chain (kappa), and
B and D bands were the controls.
4.5. Characterization of Monoclonal Antibody
The results of cross-reactivity of different recombinant
proteins with the MAb (FRP92) are shown in Table 4. The
recombinant protein used in these studies was obtained
from Abcam.
4.6. SDS-PAGE and Western Blotting to Determine the Molecular
Weight of Antigen
To determine the molecular weight of antigen in blad-
der cancer tissue, SDS-PAGE (10%) and Western blotting
were performed. The results are shown in Figure 2. Bands
of approximately 40 - 50 KD for antigen were obtained. The
results of western blot analysis of cell line lysate (MCF-7,
HpG2, MDA-MB-468, HN5, and A431) and tumor tissue blad-
der were also shown.
Figure 2. SDS-PAS of Tissue and Cell Lysates
M: MW marker, B : tumoral bladder tissue, C: HN5, D: HpG2, E: MDA-MB-468, F: MCF-7.
4.7. Calculating the Affinity of FPR92
The concentration of purified antibody was measured
by the Bradford method (555 ug/mL equivalent to 333 nM).
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Table 1. Mouse Polyclonal Antibody Titer After Injection With the Recombinant Protein NMP22
Mice Number Serum Dilution
1/500 1/1000 1/2000 Normal Mouse Serum 1/500
1-(OD450 nm) 3.5 3.5 3.2 1.1
2-(OD 450 nm) 3.5 3.5 3.5 1.1
Table 2. Classification of Obtained Clones, Based on the Reaction With the Recombi-
nant Antigen
Absorption The Number of Clones
High absorption > 3 OD450 nm 25
Absorbing between 2.5 to 3 OD450 nm 47
Absorbing between 2 to 2. 5 OD450nm 73
SUM 135
Different concentrations of the antigen was coated and re-
acted with different concentrations of the antibodies. The
results are summarized in Figure 3. The affinity was calcu-
lated as 3× 10-7 M-1 for the clone named FRP92.
Figure 3. Western Blot Analysis
M: weight marker, A: MCF-7, B: MDA-MB-468, C: HN5, D: bladder tumor tissue (de-
tected with the monoclonal Ab produced in this study). Note the bands at the region
of 40 and 55 KDs. Ab concentration : [10-7 M-1]
5. Discussion
Nmp22 is a member of the intermediate filament pro-
teins families. This protein is released in different cells
when apoptosis is taking place. Monoclonal antibodies
produced against nmp22, can be used in diagnostic im-
munohistochemistry, in detection of carcinoma of the
bladder and bladder carcinoma metastasis (23, 24). The
















5.75                     11                          23                        46
Nono mole of Antibody
Calculated to be 3× 10-7 M-1
described experiment using the standard hybridoma tech-
nique (25), for specific MAbs production and detection of
proteins of interest can be easily reproduced. However, it
is not always straight-forward to obtain MAbs that have all
respected properties. In this study, a nmp22 recombinant
protein was injected to balb/c mouse, while our attempt to
use bladder tissue to raise the antibody failed (26). A num-
ber of researchers have used tissue for generation of anti-
body against the respective antigen (27), however for the
reasons not clear for us it was not possible to use these anti-
gens in case of nmp22 antigen. Four weeks after the first in-
jection with the recombinant protein, we obtained a high
titer polyclonal antibody. Only two weeks after the first fu-
sion, 135 clones were obtained; their optical densities were
between 2.5 to 3.5, measured using a direct ELISA system.
However, only 15 healthy clones remained after the first
limiting dilution. These clones were selected for a second
limiting dilution. At the end, we only selected eight clones
with stable optical densities of over 3. One of the clones
named FPR92 was selected and further characterized. To
detect the class and subclass of monoclonal antibodies
produced by the clone FRP92, antibody isostrip kits were
used showing that the antibody was of IgG2aκ type. For an-
tibody purification we performed ammonium sulfate pre-
cipitation. After dialysis of the product, further purifica-
tion was done by using G protein Sepharose column chro-
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Table 3. Absorption of Fifteen Selected Clones that Reacted With the Recombinant Protein nmp22
Clone Number OD450 nm Clone Number OD450 nm Clone Number OD450 nm
123 2.8 98 2.3 77 1.9
122 2.9 90 2.7 56 2.4
120 3 89 3 44 3
100 2 79 2 33 2.3
99 2.8 78 2.4 22 3
Table 4. Optical Densities, When the Antibody Reacted With Different Recombinant Antigens at the Same Concentration (1 ug /mL)
Coated Protein Nmp22 P2 CD147 Ck19 P6 BSA P5
OD450 nm 3.5 0.2 0.4 0.26 0.2 0.2 0.2
matography. The concentration of antibody purified in
this manner was found to be 550 micrograms per milliliter.
In order to detect the reactivity of the antibody with the
antigen of interest obtained from tissue, we performed
an immune-precipitation experiment where the tissue ex-
tract reacted with the polyclonal antibody. The product pu-
rified by centrifugation was separated from antibody con-
jugated sepharose using glycine buffer, centrifuged, elec-
trophoresed and blotted using the monoclonal antibody
produced in this study (FRP92) as the detector antibody.
Bands at the region of 40 KD - 55 KD in both bladder tis-
sue extract as well as some cell line extracts were observed.
It has been shown by other researches (9), that other pro-
teins of the same filamentous protein subfamily (such as
cytokeratin, bcla and KI67) exhibit a molecular weight of
40 - 50 KD and sometimes a homology of more than 70% is
found in between these proteins and the protein nmp22.
In some other studies it has already been reported that
nmp22 was degraded during cell death rising to many frac-
tions in which the 40 KD protein is predominant (9). Our
experience with this protein (nmp22) showed that even
freeze towing will degrade and produce various small frag-
ments. The cross-reactivity experiment of FPR92 with var-
ious antigens, including BSA, CK antigen (CK 19) and re-
combinant antigens, such as P5 of muc1, P6 (related pro-
teins in skeletal intermediate), p8 (EFGR of cell surface anti-
gens), P6 and CD147 was performed showing minimal cross
reactions with the antibody as compared to antigen nmp
22. Furthermore in the present study, the antibody was re-
acted with bladder tumor tissue extracts and cell lines such
as MCF7, MDA-MB-468, and HepG2 extracts in Western blot
analysis. The results of Western blotting indicated the pres-
ence of two distinct bands at molecular weights of 40 and
55 KD, respectively, which has been reported by other re-
searches (9).
Eight out of 15 antibodies showed significant binding
towards the recombinant protein (nmp22) with optical
density ranging from 2.5 to 3.5 in indirect ELISA. The affinity
of antibodies towards nmp22 was calculated to be 3× 107.
Compared with other antibodies reported by other work-
ers in our lab, such as antibodies produced against MUC1 (3
× 108) (18), melatonin (109) (19) and antibodies produced
against lung cancer tissue by others (7× 107 ) is compara-
ble. In conclusion, the newly generated antibody reacted
with truncated recombinant Numa and with the Numa ex-
pressing bladder cell lines and bladder cancer tissue ex-
tract.
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